PMID- 31690372
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20201105
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 40
IP  - 6
DP  - 2019 Nov 1
TI  - Allergen immunotherapy: definition, indications, and reactions.
PG  - 369-371
LID - 10.2500/aap.2019.40.4249 [doi]
AB  - Specific allergen immunotherapy is the administration of increasing amounts of 
      specific allergens to which the patient has type I immediate hypersensitivity. It 
      is a disease-modifying therapy, indicated for the treatment of allergic rhinitis, 
      allergic conjunctivitis, allergic asthma, and Hymenoptera hypersensitivity. 
      Specific immunoglobulin E (IgE) antibodies for appropriate allergens for 
      immunotherapy must be documented. Indications for allergen immunotherapy include 
      (1) inadequate symptom control despite pharmacotherapy and avoidance measures; 
      (2) a desire to reduce the morbidity from allergic rhinitis and/or asthma, or 
      reduce the risk of anaphylaxis from a future insect sting; (3) when the patient 
      experiences undesirable adverse effects from pharmacotherapy; and (4) when 
      avoidance is not possible. Several studies reported that immunotherapy in 
      allergic rhinitis seems to prevent the development of new allergic sensitizations 
      and/or new onset asthma. Humoral-, cellular-, and tissue-level changes occur with 
      allergen immunotherapy, including induction of allergen-specific regulatory T and 
      B cells, interleukin 10, and transforming growth factor beta production; suppression 
      of T-helper type 2 cell proliferation; large increases in anti-allergen IgG4 
      antibodies; and reduction in basophil, mast cell, and eosinophil mediator 
      release. Allergen immunotherapy can be administered either subcutaneously in the 
      physician's office or sublingually by the patient at home. The use of 
      immunotherapy in food allergy is still under investigation.
FAU - Lei, Dawn K
AU  - Lei DK
FAU - Saltoun, Carol
AU  - Saltoun C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Allergens)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens/administration & dosage
MH  - Anaphylaxis/prevention & control
MH  - Desensitization, Immunologic/*methods
MH  - Humans
MH  - Hypersensitivity, Immediate/complications/*therapy
MH  - Immune System/cytology/immunology
MH  - Immunoglobulin E/immunology
MH  - Insect Bites and Stings/immunology
EDAT- 2019/11/07 06:00
MHDA- 2020/11/06 06:00
CRDT- 2019/11/07 06:00
PHST- 2019/11/07 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - 10.2500/aap.2019.40.4249 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2019 Nov 1;40(6):369-371. doi: 10.2500/aap.2019.40.4249.